Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

77 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, Comis S, Laffranchi B, Moll J, Burris HA. Cohen RB, et al. Among authors: comis s. Clin Cancer Res. 2009 Nov 1;15(21):6694-701. doi: 10.1158/1078-0432.CCR-09-1445. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825950 Free PMC article. Clinical Trial.
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R. Del Mastro L, et al. Among authors: comis s. J Clin Oncol. 2001 Apr 15;19(8):2213-21. doi: 10.1200/JCO.2001.19.8.2213. J Clin Oncol. 2001. PMID: 11304774 Clinical Trial.
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, Laffranchi B, Comis S, de Jonge MJ, Gelderblom H, Guchelaar HJ. Steeghs N, et al. Among authors: comis s. Invest New Drugs. 2011 Oct;29(5):953-62. doi: 10.1007/s10637-010-9405-7. Epub 2010 Feb 25. Invest New Drugs. 2011. PMID: 20182906 Free PMC article. Clinical Trial.
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P, Casaretti R, De Vita F, Avallone A, Orditura M, Petrillo A, Gravina A, Faranda A, Comis S, Comella G, Catalano G. Comella P, et al. Among authors: comis s. Ann Oncol. 1999 Aug;10(8):915-21. doi: 10.1023/a:1008339010655. Ann Oncol. 1999. PMID: 10509152 Free article. Clinical Trial.
Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.
Riccardi A, Danova M, Paccagnella A, Giordano M, Favaretto A, Panozzo M, Ghiotto C, Comis S, Fiorentino M, Chieco-Bianchi L, et al. Riccardi A, et al. Among authors: comis s. Ann Hematol. 1993 Apr;66(4):185-93. doi: 10.1007/BF01703234. Ann Hematol. 1993. PMID: 8387346 Clinical Trial.
Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L, et al. Paccagnella A, et al. Among authors: comis s. Cancer. 1993 Aug 1;72(3):697-706. doi: 10.1002/1097-0142(19930801)72:3<697::aid-cncr2820720312>3.0.co;2-u. Cancer. 1993. PMID: 8392903 Clinical Trial.
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, Airoldi M, Schena M, MacArthur R, Weitman S, Jannuzzo MG, Crippa S, Fiorentini F, Petroccione A, Comis S. Caponigro F, et al. Among authors: comis s. Cancer Chemother Pharmacol. 2010 Jul;66(2):389-94. doi: 10.1007/s00280-009-1175-6. Epub 2009 Nov 22. Cancer Chemother Pharmacol. 2010. PMID: 20480279 Clinical Trial.
77 results